Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Jerome Siegmeister

Child & Adolescent Psychiatry Miami, FL Medical Doctor

NPI 1700248077 CMS profile 11306694

3850 Bird Rd Fl 10, Miami, FL 33146

Open in the dashboard

General payments

$2,999

138 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jerome Siegmeister of Miami, FL is reported in the CMS Open Payments database as having received $2,999 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $944 42
2022 General $1,933 95
2021 General $123 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerome Siegmeister
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Jerome Siegmeister were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Jerome Siegmeister Child & Adolescent Psychiatry median Middle half National median
2019 $0 $129 $42–$419 $163
2020 $0 $81 $28–$226 $114
2021 $123 $115 $31–$326 $132
2022 $1,933 $124 $40–$382 $149
2023 $944 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $0 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Otsuka America Pharmaceutical, Inc. $503 22 payments
  2. AbbVie, Inc. $487 33 payments
  3. Janssen Pharmaceuticals, Inc $327 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $284 12 payments
  5. Indivior Inc. $281 12 payments
  6. Teva Pharmaceuticals USA, Inc. $255 8 payments
  7. Alkermes, Inc. $224 11 payments
  8. Corium, Inc. $145 7 payments
  9. Lundbeck LLC $120 6 payments
  10. Axsome Therapeutics, Inc. $110 4 payments
  11. Other $264 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,999 138 payments
Products named General payments · program years 2021–2023
  1. VRAYLAR $487 33 payments
  2. REXULTI $440 19 payments
  3. SPRAVATO $327 12 payments
  4. TRINTELLIX $284 12 payments
  5. AUSTEDO $255 8 payments
  6. LYBALVI $224 11 payments
  7. ARISTADA Cns $224 11 payments
  8. ARISTADA Cns $224 11 payments
  9. PERSERIS $203 9 payments
  10. ARISTADA INITIO $162 8 payments
  11. Other $1,123 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

74

Median for Neuropsychiatry: 88

Drug cost

$1,173

Median for Neuropsychiatry: $2,689

Branded share of claims

17.6%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 16 $395
Alprazolam Generic 11 $293
Quetiapine Fumarate Er Quetiapine Fumarate Brand 13 $190
Escitalopram Oxalate Generic 14 $152
Buspirone Hcl Generic 20 $143

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record